Arcturus Therapeutics Holdings Inc.
ARCT Nasdaq
SEC CIK 1768224
Follow Arcturus Therapeutics
Weekly email: filings, results
Revenue, last quarter
$18.3M
+6.7% vs same quarter last year
Net income
−$7.4M
+44.9% vs same quarter last year
EPS, diluted
−$0.26
+46.9% vs same quarter last year
Operating cash flow
−$6.9M
+59.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $82M | −$65.8M |
| FY24 | $152.3M | −$80.9M |
| FY23 | $166.8M | −$29.7M |
| FY22 | $206M | $9.3M |
| FY21 | $12.4M | −$203.7M |
| FY20 | $9.5M | −$72.1M |
| FY19 | $20.8M | −$26M |
| FY18 | $15.8M | −$21.8M |
| FY17 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −93% | −80.2% |
| FY24 | −62.8% | −53.1% |
| FY23 | −46.9% | −17.8% |
| FY22 | 5.9% | 4.5% |
| FY21 | −1641.3% | −1648% |
| FY20 | −749.8% | −756.3% |
| FY19 | −122.7% | −125% |
| FY18 | −138.5% | −138.3% |
| FY17 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$74.5M |
| FY24 | −$60.4M |
| FY23 | −$21M |
| FY22 | $24.3M |
| FY21 | −$138.4M |
| FY20 | −$44.6M |
| FY19 | −$7.3M |
| FY18 | −$22.2M |
| FY17 | - |
- Arcturus Therapeutics
- Healthcare median
Show the numbers
| Year | Arcturus Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −80.2% | −30.6% |
| FY24 | −53.1% | −47% |
| FY23 | −17.8% | −58% |
| FY22 | 4.5% | −80.4% |
| FY21 | −1648% | −71.8% |
| FY20 | −756.3% | −62.2% |
| FY19 | −125% | −46.2% |
| FY18 | −138.3% | −49.6% |
| FY17 | - | −45.9% |